National and local summits highlight needs
In July, the Cancer Moonshot initiative organized national and local summits to discuss cancer research, treatment and prevention needs and the efforts being planned to address them.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Vice President Joe Biden, who heads the White House Moonshot program to accelerate the search for cures, assured summit participants that he’s good at “removing stuff,” meaning the bureaucratic red tape that can impede progress. The vice president also announced new public- and private-sector investments, policies, collaborations and other actions intended to help meet the Moonshot’s goal to make a decade of advances in cancer prevention, diagnosis, treatment and care in five years.
The latest developments are encouraging, writes Taussig Cancer Institute Chairman Brian J. Bolwell, MD, FACP, of Cleveland Clinic Cancer Center, who met Biden for a post-summit tour of Cleveland Clinic’s Langston Hughes Community Health and Education Center, which facilitates cancer prevention and screening.
Obstacles to cancer research and clinical trials, access to basic care in underserved communities and the soaring cost of cancer treatment are among the “stuff’ that the Moonshot program will need to tackle, Dr. Bolwell notes in a commentary for Fox News.
Read his full column here.
Photo Credit: ©Russell Lee
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients